April 13, 2007
Allergan Inc. said a U.S. federal appeals court ruled in favor of the company in a patent infringement suit against Apotex Inc., a Canadian generic-drug maker. The ruling bars Apotex from obtaining Food and Drug Administration approval to market a generic version of Irvine-based Allergan's eye drug Acular.
December 9, 2006 |
A federal appeals court upheld Friday an injunction preventing Apotex Corp. from selling its generic version of Plavix, a blockbuster blood thinner marketed by Bristol-Myers Squibb and Sanofi-Aventis. The U.S. Court of Appeals for the Federal Circuit in Washington upheld the injunction issued in August by the U.S. District Court for the Southern District of New York.
September 1, 2006 |
Bristol-Myers Squibb Co. and Sanofi-Aventis on Thursday won a bid to stop Apotex Inc. from selling its cheaper generic version of the Plavix heart pill, the world's second-biggest-selling medicine. Bristol-Myers shares surged. U.S. District Court Judge Sidney H. Stein in New York ruled that Bristol-Myers and Sanofi were likely to win their patent-infringement suit against Apotex and wouldn't be able to recoup losses if generic sales were allowed to continue.
August 15, 2006 |
Bristol-Myers Squibb Co. and Sanofi-Aventis said Monday that they filed for an injunction against Apotex Corp. to stop the Canadian drug maker from selling a less expensive, generic version of blood thinner Plavix and force it to recall product already sold. The companies also said they had begun discounting Plavix to stem the loss of market share. A hearing on the motion is set for Friday in the U.S.
January 4, 2006 |
Allergan Inc. said it won a ruling temporarily blocking Apotex Inc. from making or selling a generic version of a treatment for eye inflammation. The ruling, issued Dec. 29 by U.S. District Judge Martin Jenkins in San Francisco, temporarily prohibits Apotex from manufacturing or selling a generic version of Allergan's Acular in the U.S., Allergan spokeswoman Caroline Van Hove said. Irvine-based Allergan, which also makes the anti-wrinkle drug Botox, sued Apotex over patents for Acular in 2001.
May 19, 2005 |
A U.S. appeals court Wednesday gave generic-drug maker Apotex Inc. a second chance to seek the invalidation of a patent for Acular, Allergan Inc.'s treatment for eye inflammations. The U.S. Court of Appeals for the Federal Circuit in Washington ruled that a San Francisco judge committed a "clear error" when he concluded that Allergan's patent was valid because it wasn't an obvious variation of earlier known compounds.